Cidara Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeffrey L. Stein
- Full Time Employees
- 38
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6310 Nancy Ridge Drive San Diego CA United States of America 92121
- IPO Date
- Apr 15, 2015
- CIK
- 0001610618
- Website
- cidara.com
- Similar Companies
- Business
- Cidara Therapeutics, Inc. (Nasdaq: CDTX) is a biotechnology company that develops targeted immunotherapies using its proprietary Cloudbreak platform to create novel drug-Fc conjugates (DFCs), which couple small molecules or peptides to a human antibody fragment to inhibit disease targets while engaging the immune system; its lead product candidate, CD388, is a long-acting antiviral in Phase 3 trials for universal prevention and treatment of seasonal and pandemic influenza, with additional DFCs including CBO421 targeting CD73 for solid tumors, and preclinical and discovery programs addressing cancer, autoimmune diseases, and other serious fungal, bacterial, and viral infections. Founded in 2012 and headquartered in San Diego, California, the company focuses on high-risk patient populations including immunocompromised individuals and those facing invasive fungal infections or oncology needs, with operations primarily in the United States. In November 2025, Cidara entered a definitive agreement to be acquired by Merck for approximately $9.2 billion at $221.50 per share in cash, a transaction pending stockholder approval and regulatory clearance expected in early 2026, following CD388's FDA Breakthrough Therapy designation, a $339 million BARDA funding award for U.S. manufacturing and commercialization, a $402.5 million equity raise in June 2025, and regaining full global rights to CD388 from Janssen in April 2024 for $85 million.
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above Fifty Day Moving Average – Should You Sell?
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
3,187 Shares in Cidara Therapeutics, Inc. $CDTX Bought by ANB Bank
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of “Hold” from Analysts
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Hold” from Brokerages
3 Potential Mid-Cap Biotech Buyout Targets In 2026
Geode Capital Management LLC Grows Stock Position in Cidara Therapeutics, Inc. $CDTX
Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights
HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN
hVIVO gains validation from Cidara's takeover; broker calls it a "glowing endorsement"
hVIVO hails $9.2 billion Cidara takeover after key trial wins
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025
Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover